Skip to content
Unrated Drug recall · FDA · Published October 29, 2024

Viona Dapsone Gel 7.5% Recall: Crystallization Risk

Viona Pharmaceuticals recalls Dapsone Gel 7.5% (60g pump) due to crystallization risk. Affected lots expire June 2026 or March 2026. Stop using immediately if you have this medication.

🇺🇸 FDA recall #D-0038-2025DrugViona Pharmaceuticals ›
Take action

Contact the company

Recalling firmVIONA PHARMACEUTICALS INC20 Commerce Dr Ste 340 · Cranford, NJ 07016-3617
✎ GovInfoNow plain-language explainer

Viona Pharmaceuticals is recalling Dapsone Gel 7.5% (60g pump) because it may crystallize, which could cause problems. This is a prescription-only medication that was manufactured in India and distributed in the U.S. The recall affects specific batches with expiration dates in 2026. Read more at govinfonow.com/recall/32481-viona-dapsone-gel-7-5-recall-crystallization-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/32481-viona-dapsone-gel-7-5-recall-crystallization-risk · Updated September 23, 2026 · FDA enforcement record: FDA #D-0038-2025

Cite this page

“Viona Dapsone Gel 7.5% Recall: Crystallization Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32481-viona-dapsone-gel-7-5-recall-crystallization-risk. Based on FDA recall #D-0038-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0038-2025%22&limit=1).

Viona Pharmaceuticals Inc. recalled Dapsone Gel 7.5% due to crystallization, the Food and Drug Administration said on Oct. 29, 2024. The voluntary Class II recall affects 6,048 pumps distributed nationwide.

How to tell if you have it

  • Brand: Viona Pharmaceuticals
  • Product: Dapsone Gel 7.5%, 60 gram pump
  • NDC: 72578-094-02
  • Lot codes: T401151 (Exp 06/30/2026), T400806 (Exp 03/31/2026)
  • Manufacturer: Zydus Lifesciences Ltd., Ahmedabad, India
  • Distributor: Viona Pharmaceuticals Inc., Cranford, NJ 07016
  • Quantity: 6,048 pumps

The hazard

The recall addresses crystallization in the gel. The FDA classified the issue as a Class II recall.

Context

GovInfoNow's records show Viona Pharmaceuticals Inc. has six other recalls on record since June 1, 2021. Other recent recalls of similar products include Endo USA Buprenorphine Injection Recall: Crystallization Risk (March 13, 2026), Sun Pharmaceutical Diclofenac Gel Recall: Failed Viscosity Specifications (Jan. 27, 2026), and Par Health Buprenorphine Injection Recall: Crystallization Risk (June 12, 2026).

How to tell if you have this one

Check the product label for the lot number: T401151 (expires June 30, 2026) or T400806 (expires March 31, 2026). This medication is a prescription-only gel used for specific medical conditions.

  • Brand
    Viona Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Stop Using Immediately

    If you have the recalled Dapsone Gel 7.5% (60g pump) with lot numbers T401151 or T400806, stop using it right away.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 15 days after the firm started it.

1. Firm started the recall: Oct 29, 202412. FDA classified it Class II: Nov 5, 202423. Published in FDA’s Enforcement Report: Nov 13, 202432024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0038-2025 (October 29, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0038-2025 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA